Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report

Mugabure Bujedo Borja

doi:doi:10.11648/j.ajim.s.2014020601.11

| Peer-Reviewed

Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report

Mugabure Bujedo Borja

Published in American Journal of Internal Medicine (Volume 2, Issue 6-1)

Received: 18 October 2014 Accepted: 12 December 2014 Published: 7 January 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.

Published in	American Journal of Internal Medicine (Volume 2, Issue 6-1) This article belongs to the Special Issue Neuropathic Pain
DOI	10.11648/j.ajim.s.2014020601.11
Page(s)	1-4
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Chronic Pain, Neuropathic Pain, Opioids, Tapentadol, Oxaliplatin

References

[1]	Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C.Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008; 136(3): 380-7.
[2]	McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013; 8: CD006146.
[3]	Velasco R, Bruna J. Chemotherapy-induced neuropathy: a problem unresolved. Neurology. 2010; 25 (2): 116-131
[4]	Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1(4): 249–258
[5]	Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013; 16 (1): 27-40.
[6]	Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol extended release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27 (6): 381-99.
[7]	Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014; 28 (4): 319-29
[8]	Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical Considerations for the Use of Tapentadol Prolonged Release for the Management of Severe Chronic Pain. Clin Ther. 2014; S0149-2918 (14) 00445-7. [Epub ahead of print]
[9]	Pierce DM, Shipstone E. Pharmacology: tapentadol for neuropathic pain. Am J Hosp Palliat Care. 2012; 29 (8): 663-6
[10]	Smith HS. Opioids and neuropathic Pain. Pain Physician. 2012; 15 (3 Suppl): ES 93-110

Cite This Article

Plain Text BibTeX RIS

APA Style

Mugabure Bujedo Borja. (2015). Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. American Journal of Internal Medicine, 2(6-1), 1-4. https://doi.org/10.11648/j.ajim.s.2014020601.11

Copy | Download

ACS Style

Mugabure Bujedo Borja. Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. Am. J. Intern. Med. 2015, 2(6-1), 1-4. doi: 10.11648/j.ajim.s.2014020601.11

Copy | Download

AMA Style

Mugabure Bujedo Borja. Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. Am J Intern Med. 2015;2(6-1):1-4. doi: 10.11648/j.ajim.s.2014020601.11

Copy | Download

@article{10.11648/j.ajim.s.2014020601.11,
  author = {Mugabure Bujedo Borja},
  title = {Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report},
  journal = {American Journal of Internal Medicine},
  volume = {2},
  number = {6-1},
  pages = {1-4},
  doi = {10.11648/j.ajim.s.2014020601.11},
  url = {https://doi.org/10.11648/j.ajim.s.2014020601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.s.2014020601.11},
  abstract = {Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report
AU  - Mugabure Bujedo Borja
Y1  - 2015/01/07
PY  - 2015
N1  - https://doi.org/10.11648/j.ajim.s.2014020601.11
DO  - 10.11648/j.ajim.s.2014020601.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 1
EP  - 4
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.s.2014020601.11
AB  - Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.
VL  - 2
IS  - 6-1
ER  -

Copy | Download

Author Information

Mugabure Bujedo Borja

Department of Anesthesiology, Critical Care and Pain Medicine, Donostia University Hospital, San Sebastian, 20014, Spain

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mugabure Bujedo Borja. (2015). Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. American Journal of Internal Medicine, 2(6-1), 1-4. https://doi.org/10.11648/j.ajim.s.2014020601.11

Copy | Download

ACS Style

Mugabure Bujedo Borja. Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. Am. J. Intern. Med. 2015, 2(6-1), 1-4. doi: 10.11648/j.ajim.s.2014020601.11

Copy | Download

AMA Style

Mugabure Bujedo Borja. Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report. Am J Intern Med. 2015;2(6-1):1-4. doi: 10.11648/j.ajim.s.2014020601.11

Copy | Download

@article{10.11648/j.ajim.s.2014020601.11,
  author = {Mugabure Bujedo Borja},
  title = {Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report},
  journal = {American Journal of Internal Medicine},
  volume = {2},
  number = {6-1},
  pages = {1-4},
  doi = {10.11648/j.ajim.s.2014020601.11},
  url = {https://doi.org/10.11648/j.ajim.s.2014020601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.s.2014020601.11},
  abstract = {Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report
AU  - Mugabure Bujedo Borja
Y1  - 2015/01/07
PY  - 2015
N1  - https://doi.org/10.11648/j.ajim.s.2014020601.11
DO  - 10.11648/j.ajim.s.2014020601.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 1
EP  - 4
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.s.2014020601.11
AB  - Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.
VL  - 2
IS  - 6-1
ER  -

Copy | Download